T-Knife
T-Knife develops T cell receptor engineered T cell therapies for patients with solid tumors.
$110M Series B+ ·
Led by Fidelity · Source: fundraisingfox.com
Total raised: $188M across 2 sourced rounds
All 2 rounds ↓Signals
About T-Knife
The company designs T cell therapies using proprietary platforms and synthetic biology capabilities. T-Knife is a biopharmaceutical company.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $110M | fundraisingfox.com | ||
| Series A | $78M | bioworld.com |
Timeline
- Website created
Founders and team
EK
Elisa Kieback Founder- TBThomas Blankenstein Scientific Foundersource: t-knife.com
CL
Camille Landis CBO / CFOSS
Simone Silva Steiner Chief Technical Operations OfficerTS
Tom Soloway Chief Executive Officer
Investors
AAndera Partners
BBoehringer Ingelheim Venture Fund
CCaaS Capital Management
CCasdin Capital
EEQT Life Sciences
FFidelitylead investor
QQatar Investment Authority
RRA Capital Managementlead investor
SSixty Degree Capital
VVersant Ventureslead investor
Companies like T-Knife
IIDRx$120M Series B+ · Aug 2024
WWaypoint Bio$20M Series A · Jun 2026
AArsenal BiosciencesSeries B+ · Oct 2025
SSyntax$14.4M · Jun 2026AA2 Biotherapeutics$80M Series B+ · Jan 2025
TThird Arc Bio$52M Series A · Feb 2026
Other companies backed by Fidelity
HHarbinger$240M Series B+ · Nov 2026
SSoufflé Therapeutics$135M Series B+ · Oct 2026
MMMI$125M Series B+ · Oct 2026
SSiMa AI$150M Series B+ · Sep 2026
EEpicrispr Biotechnologies$90M Series B+ · Aug 2026
RRedwood Materials$550M Series B+ · Jul 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/t-knife (get a free API key).